Numerous studies have focused on the association of methionine synthase (MS) A2756G polymorphism and acute hematological cancer risk. However, the results remain inconsistent. Therefore, a meta-analysis was performed to derive a more precise estimate of the association between them.Methods:
This meta-analysis involved 25 articles (26 studies) including 8641 hematological cancer patients and 15,498 controls. The pooled odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) of the association between MS A2756G polymorphism and the risk of hematological cancer were calculated.Results:
Overall, no significant increased risks were found between MS A2756G polymorphism and hematological cancer risk under allelic homozygote (GA vs AA: OR = 0.98, 95% CI = 0.89–1.07, P = .62), heterozygote (GG vs AA: OR = 0.99, 95% CI = 0.85–1.15, P = .91), dominant (AG+GG vs AA: OR = 0.99, 95% CI = 0.90–1.08, P = .93), and recessive (GG vs AG+AA: OR = 1.00, 95% CI = 0.86–1.16, P = .97) models, respectively. In the stratified analyses by ethnicity and source of controls, there were still no significant associations between them in all genetic models.Conclusions:
Therefore, these findings demonstrate that MS A2756G polymorphism may not be a risk factor for hematological cancer.